Signaturefd 13F: Adds $2.9M to SUPN Stake
Key Points
- Signaturefd added 66,227 shares of Supernus Pharmaceuticals (SUPN), raising its total to 66,754 shares valued at approximately $2.87 million.
- The stock recently traded around $40.70, which is 31.8% below its 52-week high of $59.68.
- Other institutional investors, including Millennium Management and Armistice Capital, also hold significant positions in Supernus Pharmaceuticals.
Get Supernus Pharmaceuticals text alerts
We text you when insiders, Congress, analysts or big funds move on $SUPN.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Supernus Pharmaceuticals, Inc. alert may contain errors. Disclosures
Signaturefd has boosted its position in Supernus Pharmaceuticals, Inc. (SUPN) by adding 66,227 shares in a filing on October 23, 2026. This increase raises its total holdings to 66,754 shares, valued at about $2.87 million.
SUPN
Supernus Pharmaceuticals, Inc.
Signaturefd vs. the S&P 500
Hypothetical returns from Signaturefd's disclosed trades, not real profit or advice. How we model this.
Where Supernus Pharmaceuticals Fits in Signaturefd's Portfolio
This investment represents 0.05% of Signaturefd's reported 13F portfolio, ranking 51 out of 3,528 positions.
Other Institutional Activity in Supernus Pharmaceuticals
Several other funds have also adjusted their positions in Supernus Pharmaceuticals. Millennium Management LLC increased its holdings by 537,195 shares, bringing its total to 3,853,212 shares worth approximately $156.8 million. Armistice Capital, LLC added 750,913 shares for a total of 2,646,201 shares valued at about $107.7 million. Nomura Asset Management International Inc also grew its stake, acquiring 341,042 shares for a total of 2,378,329 shares valued at roughly $96.8 million.
Supernus Pharmaceuticals, Inc. Stock Down 3.3%
Supernus Pharmaceuticals traded recently around $40.70, which is below its 50-day moving average of $43.20 and its 200-day average of $47.54. The stock is currently 31.8% below its 52-week high of $59.68 but 8.4% above its 52-week low of $37.54.
Recent Earnings
Supernus Pharmaceuticals reported trailing twelve-month revenue of approximately $830.4 million and a net loss margin of 13.2%. The next earnings report is expected on October 29, 2026.
Insider Buying and Selling at Supernus Pharmaceuticals, Inc.
Insiders have sold shares recently, including Officer William Todd Horich, who sold 8,877 shares on March 10, 2026, and Director Frederick M Hudson, who sold 5,369 shares on March 12, 2026, at an average price of $50.61. CEO Jack A. Khattar also sold 35,000 shares on March 13, 2026.
Analysts Set New Price Targets
On July 9, 2026, Cantor Fitzgerald maintained an Overweight rating on Supernus Pharmaceuticals with a price target of $67.00, up from a previous target of $63.00. The consensus recommendation for the stock is a strong buy, with a mean target price of $60.50.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company based in Rockville, Maryland. It focuses on developing and marketing products for treating central nervous system diseases in the United States. This recent increase in Signaturefd's stake may reflect confidence in Supernus's growth prospects in the healthcare sector.
Bottom Line
Investors should watch for Supernus Pharmaceuticals' upcoming earnings report on October 29, 2026, to gauge its financial health. Signaturefd's substantial increase in shares indicates a growing belief in the company's future performance.
Related Filing Alerts
Source: Signaturefd's 13F filing on $SUPN (Oct 23, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts